Bio-Rad Laboratories Down Over 6%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones11-16

Bio-Rad Laboratories, Inc. Class A $(BIO)$ is currently at $328.30, down $21.93 or 6.26%

 

--Would be lowest close since Oct. 25, 2024, when it closed at $320.23

--On pace for largest percent decrease since Oct. 27, 2023, when it fell 7.15%

--Currently down eight consecutive days; down 12.28% over this period

--Longest losing streak since April 19, 2024, when it fell for eight straight trading days

--Worst eight day stretch since the eight days ending April 22, 2024, when it fell 15.39%

--Down 8.34% month-to-date

--Up 1.68% year-to-date; on pace for best year since 2021, when it rose 29.61%

--Down 60.24% from its all-time closing high of $825.77 on Sept. 2, 2021

--Up 9.67% from 52 weeks ago (Nov. 17, 2023), when it closed at $299.36

--Down 12.28% from its 52-week closing high of $374.28 on Nov. 5, 2024

--Up 24.37% from its 52-week closing low of $263.97 on July 1, 2024

--Traded as low as $327.45; lowest intraday level since Oct. 29, 2024, when it hit $325.66

--Down 6.5% at today's intraday low; largest intraday percent decrease since April 18, 2024, when it fell as much as 7.54%

 

All data as of 12:11:41 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 15, 2024 12:13 ET (17:13 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment